浙江昂利康制药股份有限公司 关于获得药品注册证书的公告

Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. has received the drug registration certificate for the combination drug Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration, which is expected to enhance the company's product pipeline [1][2]. Group 1: Drug Information - The Sitagliptin Metformin Extended-Release Tablets are a compound formulation intended for adult patients with type 2 diabetes who are currently receiving treatment with Sitagliptin and Metformin Extended-Release Tablets [1]. - The company received the acceptance notice for the drug's marketing authorization application in January 2024 and has recently obtained the drug registration certificate, which is considered equivalent to passing the consistency evaluation according to national policies [1]. Group 2: Impact on the Company - The approval of Sitagliptin Metformin Extended-Release Tablets will further enrich the company's product pipeline [2]. - Due to the unique nature of the pharmaceutical industry, drug sales may be significantly affected by national policies and market environment changes, leading to considerable uncertainty in specific sales outcomes [2].